
The Federal Trade Commission (FTC) has intervened to halt a significant healthcare deal in California. The FTC has taken issue with the proposed acquisition by nonprofit John Muir Health of Tenet Healthcare’s majority stake in San Ramon Regional Medical Center for $142.5 million.
John Muir Health, which has held a 49% interest in San Ramon Regional Medical Center since 2013, had revealed plans earlier in the year to acquire full ownership and operational control of the 123-bed facility. However, the FTC contends that this consolidation would lead to decreased competition and higher healthcare costs for consumers in the I-680 corridor of California.
According to the FTC’s release, the primary competitors for inpatient general acute care in the relevant area are two other hospitals operated by John Muir Health. If the deal were to proceed, the FTC argues that the Walnut Creek-based healthcare system would control over 50% of the market, raising concerns about monopolistic practices.
Related: FTC Sues To Stop Hospital Merger
“San Ramon Regional Medical Center has played an important role in ensuring Californians in the I-680 corridor have access to quality, affordable care for critical health care services, such as cardiac surgery and childbirth,” stated Henry Liu, Director of the FTC’s Bureau of Competition. “John Muir’s acquisition of San Ramon Medical would increase already high health care costs in the area and threaten to stall quality improvements that help advance care for all patients.”
According to Fierce Pharma, the FTC has taken decisive action by issuing an administrative complaint and authorizing a lawsuit to be filed in the U.S. District Court for the Northern District of California. The regulatory body is seeking a temporary restraining order and preliminary injunction to prevent the completion of the proposed transaction. The decision to pursue legal action was made in a unanimous 3-0 vote by the FTC’s commissioners.
Throughout its investigation, the FTC collaborated closely with the California attorney general’s office, and the latter is expected to join the court filing. The regulatory body alleges that the proposed deal would result in higher insurance premiums, co-pays, deductibles, and other out-of-pocket costs, or reduced benefits for commercial health insurance enrollees.
Source: Fierce Healthcare
Featured News
Alibaba Health’s $1.73 Billion Deal to Boost Online Health Store Services
Nov 28, 2023 by
CPI
Nvidia Faces Global Regulatory Scrutiny Amid Antitrust Investigations
Nov 28, 2023 by
CPI
Meta Plans Appeal Following Judge’s Ruling in Privacy Battle with FTC
Nov 28, 2023 by
CPI
Tiger Woods Voices Discontent Over PGA Tour’s Saudi Agreement
Nov 28, 2023 by
CPI
Global Regulators Evaluate Crypto Safeguards Amid Concerns of Financial Instability
Nov 28, 2023 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Consent Decrees
Nov 15, 2023 by
CPI
Consent Decrees Under the Biden Administration
Nov 15, 2023 by
CPI
The FTC´s Prior Approval Mischief
Nov 15, 2023 by
CPI
Fix-It-First: A Seismic Shift in U.S. Antitrust Agency Approaches to Merger Remedies
Nov 15, 2023 by
CPI
“Shadow” Settlements and the Tunney Act
Nov 15, 2023 by
CPI